Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study
Chemotherapy · 2024
DOI: 10.1159/000542101 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Chemotherapy, 2024. Verfasst von Victoria Ferrari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Antoine Lacassagne Cancer Institute, Côte d'Azur University, Nice, France. Hauptthemen laut MEDLINE: Neoplasms, Critical Care, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Themen: Intensivpflege
Abstract (Originalsprache)
Introduction
Our study aimed to identify relevant features associated with the reprisal of antineoplastic treatment in patients with solid cancers after unplanned admittance to the intensive care unit (ICU) and to assess 60th-month survival in patients with solid neoplasms admitted to the ICU.
Methods
This single-centre retrospective study of critically ill patients with active cancers was performed over a 13-year period (2005–2018). Patients’ characteristics, overall survival, and antineoplastic treatment reprisal were extracted from digital medical files and compared.
Results
134 patients were included in the study. Solid neoplasms were mostly localised to the head and neck (n = 53) followed by lung cancers (n = 29). Sepsis was the leading cause of ICU admission (62.1%) with 41/82 patients presenting with septic shock. Antineoplastic treatments were resumed in 40 patients. An age ≤60 years and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 were found to be predictors for treatment reprisal, with odd ratios of, respectively, 2.83 (95% CI, 1.15–6.99) and 5.45 (95% CI, 2.01–14.82); area under the ROC curve of 72% (95% CI, 63–81%). Survival after the immediate discharge from the ICU was 101/134 (75%) and the 60-month survival rate was 29% and significantly higher in the treatment-reprisal group.
Conclusions
Age and ECOG PS were found to be predictors for treatment reprisal in patients with solid neoplasms admitted to the ICU. The latter benefits from better long-term survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Antoine Lacassagne Cancer Institute, Côte d'Azur University, Nice, France.
- Department of Medical Intensive Care, Archet Hospital, Côte d'Azur University, Nice, France.
- Epidemiology, Biostatistic and Health Data Department, Antoine Lacassagne Cancer Institute, Côte d'Azur University, Nice, France.
- Department of Internal Medicine and Clinical Immunology, Archet Hospital, Côte d'Azur University, Nice, France.
Zitieren
APA
Ferrari, V., Morand, L., Hyvernat, H., Schiappa, R., Dellamonica, J., & Martis, N. (2024). Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study. Chemotherapy. https://doi.org/10.1159/000542101
Vancouver
Ferrari V, Morand L, Hyvernat H, Schiappa R, Dellamonica J, Martis N. Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study. Chemotherapy. 2024. doi:10.1159/000542101
BibTeX
@article{Ferrari2024,
author = {Ferrari, Victoria and Morand, Lucas and Hyvernat, Hervé and Schiappa, Renaud and Dellamonica, Jean and Martis, Nihal},
title = {Predicting Reprisal of Solid Cancer Treatment and 60-Month Survival after Medical Intensive Care: A Single-Centre Cohort Study},
journal = {Chemotherapy},
year = {2024},
doi = {10.1159/000542101}
}
EUVIMED